AtriCure Inc., which opened its office in Hacienda in 2021, is a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management. The company provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide, according to company officials. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure's Isolator Synergy Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib, while AtriCure's AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide.

Last month, AtriCure was named the top company for the 2022 Diversity, Equity, and Inclusion (DE&I) Award in the Small Cap - Public Company category. The award, given by the National Association of Corporate Directors (NACD), recognizes boards that have improved their governance and created long-term value for stakeholders by implementing forward-thinking diversity, equity, and inclusion practices.
"This award is an immense testament to the efforts of the people at AtriCure, including our Board of Directors, who understand that DE&I have to be embedded in our culture if we are to do our best work in developing innovative products and therapies that improve patients' lives," according to Board Chair B. Kristine Johnson.

AtriCure is committed to fostering a workplace that celebrates differences and advances equality, according to company officials, who say that commitment is reflected in the current makeup of the AtriCure Board, which includes a majority of female and ethnically diverse directors. Board Chair Johnson is one of only a few female Board chairs in the medical technology industry.
"AtriCure has worked to achieve great strides in creating an equitable boardroom," said NACD President and CEO Peter Gleason. "NACD is proud to honor the company for advancing DE&I in their boardroom and throughout their organization."

In addition, AtriCure has grown its talent base of women and ethnically diverse professionals, increased recruiting channels for diverse and underrepresented candidates, developed community collaborations for minority STEM applicant pipelines, and has established broad corporate training around DE&I topics, officials say. AtriCure has been named to Top Workplaces lists multiple times over the past decade as well.
"We are incredibly proud of the capable and talented Board and employees who make AtriCure a place where people feel valued," according to Michael H. Carrel, President and Chief Executive Officer of AtriCure. "We are committed to upholding an environment where our team members can bring their best selves to their work advancing our patient-first mission."

Winners of the NACD DE&I awards were selected from a group of 20 finalists and publicly announced at the 2022 NACD DEI Awards Gala held in New York City in early December. NACD is a premier membership organization for board directors who want to expand their knowledge, grow their network, and maximize their potential within an expanding community of more than 23,000 members and a nationwide chapter network.

For more information about AtriCure Inc., please visit www.atricure.com, www.linkedin.com/company/atricure, or www.twitter.com/AtriCure.